By uncovering genetic factors behind blood and urine biomarkers, researchers came up with polygenic scores related to biomarker status and related disease risk.
A transcriptomic study found 25 genes that are differentially expressed at various disease stages, suggesting the proteins they encode could serve as biomarkers.
Ymir Genomics and OHSU will share in any value created by the biomarkers and will jointly publish and validate the biomarkers in a large-scale multi-center study.
The partners will use Namocell's single-cell dispensing tool and Takara's Smart-seq technology to isolate and characterize HepaTx's hepatocyte-like cells.
Although normal tissues with somatic mutations did not necessarily progress to cancer, researchers saw a jump in mutational burden in samples associated with cancer or cirrhosis.
The researchers molecularly characterized cells found in cirrhotic tissue that express genes involved in pro-fibrogenic pathways that could be targeted by drugs.
Researchers characterized new and known cell populations with single-cell transcriptome profiles for nearly 10,400 liver cells, using the data to see changes associated with liver cancer.
Researchers found diagnostically informative single-gene mutations in five of the 19 idiopathic liver diseases cases they assessed with exome sequencing.
A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.
Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.
